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Abstract
Background: Peri-operative red blood cell transfusions (RBCT) may induce transfusion-related
immunomodulation and impact post-operative recovery. This study examined the association between
RBCT and post-pancreatectomy morbidity.
Methods: Using the American College of Surgeons National Surgical Quality Improvement Program
(ACS-NSQIP) registry, patients undergoing an elective pancreatectomy (2007–2012) were identified.
Patients with missing data on key variables were excluded. Primary outcomes were 30-day post-oper-
ative major morbidity, mortality, and length of stay (LOS). Unadjusted and adjusted relative risks (RR)
with a 95% confidence interval (95%CI) were computed using modified Poisson, logistic, or negative
binomial regression, to estimate the association between RBCT and outcomes.
Results: The database included 21 132 patients who had a pancreatectomy during the study period.
Seventeen thousand five hundred and twenty-three patients were included, and 4672 (26.7%) received
RBCT. After adjustment for baseline and clinical characteristics, including comorbidities, malignant
diagnosis, procedure and operative time, RBCT was independently associated with increased major
morbidity (RR 1.49; 95% CI: 1.39–1.60), mortality (RR 2.19; 95%CI: 1.76–2.73) and LOS (RR 1.27; 95%
CI 1.24–1.29).
Conclusion: Peri-operative RBCT for a pancreatectomy was independently associated with worse
short-term outcomes and prolonged LOS. Future studies should focus on the impact of interventions
to minimize the use of RBCT after an elective pancreatectomy.
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Introduction
Pancreatectomy is increasingly performed for both malignant
and benign indications. Post-operative mortality has decreased
over the past several years, reaching levels below 5% in high-
volume centres.1–4 However, morbidity remains high, with
reported rates ranging from 30% to 60%.1–4 This carries signif-
icant repercussions for both patients and institutions, including
delayed recovery and increased hospital costs.5
Red blood cell transfusions (RBCT) have a detrimental
impact on patients, mandating the judicious use of blood
products.6,7 In addition to well-known but uncommon haemo-
lytic reactions and infection transmission risks, RBCTs have
been incriminated in worse post-operative outcomes for a
variety of procedures.8–11 In cancer patients, RBCTs also
appear to increase recurrence and reduce survival.12–15 Several
theories exist to explain those findings, including that of
transfusion-related immunomodulation. RBCT can suppress
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immunity and create a fertile ground for complications
that compromise patient’s post-operative progress and recov-
ery.16–19 Specific data on the impact of RBCT on post-pancrea-
tectomy outcomes are limited to single institution analyses
with small numbers of patients.20,21
Despite evidence-based guidelines recommending a restric-
tive approach to RBCT use, transfusion practices vary signifi-
cantly.22–25 A large number of peri-operative RBCT are
unnecessary.21,26,27 Further information is needed regarding the
impact of RBCT on post-pancreatectomy outcomes to confirm
the need for and devise tailored strategies to address transfu-
sion practices.28,29
The purpose of this study was to examine the impact of
RBCT on short-term outcomes after elective pancreatectomy,
using the large multi-institutional American College of Sur-
geons National Surgical Quality Improvement Program (ACS-
NSQIP) dataset.
Patients and methods
Study design and population
A retrospective, cohort study was conducted using the ACS-
NSQIP dataset. Using the ACS-NSQIP Participant User File
(PUF), patients from participating institutions entered in the
registry between 1 January 2007 and 31 December 2012, who
underwent a pancreatectomy (Current Procedural Terminology
– CPT – codes 48140, 48145-6, 48150, 48152-4, 48144 and
48160) were considered eligible for the study. Additional exclu-
sion criteria included an emergent operation, age <18 years
old, or data missing on the following key variables, because of
their clinical relevance in assessing outcomes of peri-operative
RBCT: gender, American Society of Anesthesiologists (ASA)
class, pre-operative haematocrit level and cardiovascular
comorbidities (cardiac heart failure, myocardial infarction,
angina and hypertension).
There was no missing data on age. Missing data were
encountered in < 0.05% for ASA class and gender, 2% for pre-
operative haematocrit and 14% for cardiac comorbidities. Data
were missing according to year of operation and increased over
time. No data were missing on cardiac comorbidities for 2007–
2010, whereas 24.5% were missing for this variable in 2011
and 37.1% in 2012.
Data sources
The ACS-NSQIP is a multicentre prospective registry designed
to evaluate risk-adjusted outcomes of surgical patients. It
includes more than 525 hospitals from academic and commu-
nity settings, representative of various regions in North Amer-
ica. Variables collected include demographics, pre-operative
risk factors, procedural indication and details, and 30-day
post-operative morbidity and mortality. Data are collected by
trained data abstractors and audited for accuracy.30 The meth-
ods of ACS-NSQIP data collection and audits have previously
been reported.31–34
Patients’ baseline demographics, clinical characteristics,
and treatment-related details were abstracted from the PUF.
Cardiac co-morbidities were defined as a history of congestive
heart failure (in the 30 days prior to surgery), myocardial
infarction (in the 6 months prior to surgery), angina (in the
30 days prior to surgery) or medicated hypertension (30 days
prior to surgery). A malignant diagnosis was based on ICD-9
codes (156.X, 157.X and 209.X).35 The World Health Organi-
zation cut-off of haematocrit below 40% was used to define
pre-operative anaemia.36 Peri-operative RBCT was defined as
the receipt of RBCT intra-operatively or in the 72 h post-oper-
atively.30 Owing to changes in ACS-NSQIP data coding, a
dichotomous transfusion variable was created for any transfu-
sion of one or more RBC units for 2010–2012. None of the
patients were missing data on the RBCT variable.
Outcomes
Primary outcomes were 30-day major morbidity and mortality.
The major morbidity composite outcome was created based on
the occurrence of at least one of the following: deep or organ-
space surgical site infection, wound dehiscence, pneumonia,
pulmonary embolism, prolonged mechanical ventilation
beyond 48 h, unplanned re-intubation, renal failure, sepsis,
myocardial infarction, cardiac arrest, or cerebrovascular acci-
dent.1 Post-operative mortality was defined as death within
30 days of the operation.
Secondary outcomes included system-specific 30-day mor-
bidity grouped into post-operative infections [superficial, deep
and organ space-space surgical site infection (SSI), pneumonia,
urinary tract infection, sepsis and septic shock], cardiac events
(myocardial infarction, cardiac arrest), respiratory failure
(prolonged mechanical ventilation beyond 48 h, unplanned
re-intubation), venous thrombo-embolic events (pulmonary
embolism and deep vein thrombosis) and length of stay
(LOS).30
Statistical analysis
Descriptive analysis was first performed to assess the character-
istics of transfused patients and compare them to those of not
transfused patients. Unknown categories were created for miss-
ing data. Categorical data were reported as absolute number
(n) and proportion (%), and continuous data as mean or med-
ian with interquartile range (IQR). Baseline patient variables
and operative characteristics were compared between patients
who received a transfusion and those who did not. Chi-square
tests for independence were used to compare categorical vari-
ables. Normally distributed continuous data were compared
using t-tests and skewed continuous data using Wilcoxon-rank
sum tests.
Modified Poisson regression analysis was used to examine
the association between RBCT for common dichotomous out-
comes (>10%), and logistic regression for uncommon dichoto-
mous outcomes (≤10%). LOS values were treated as count
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data, but the data were skewed and violated the assumptions
of Poisson regression, therefore, negative binomial regression
was used to study the relationship between transfusion and
LOS.37 Multivariate analyses were adjusted for highly relevant
clinical characteristics defined a priori – age (continuous), body
mass index (BMI) (<20, 20–29, 30–39, 40+, unknown), race,
ASA class, pre-operative haematocrit values (continuous),
cardiac comorbidities, bleeding disorder, pre-operative Interna-
tional Normalized Ratio (INR) (categorized as normal,
abnormal and unknown), pre-operative bilirubin (categorized
as normal, abnormal and unknown), malignant diagnosis, the
surgical procedure (total pancreatectomy, distal pancreatec-
tomy and pancreatoduodenectomy) and the year of the opera-
tion and operative time (continuous). Results are reported as
relative risks (RR) with 95% confidence interval (CI). All sta-
tistical analyses were conducted using SAS 9.3 for Windows
(SAS Institute Inc., Cary, NC, USA). P-values of less than 0.05
were considered statistically significant.
To understand how the increased level of missing data over
time impacted the results, a sensitivity analysis was restricted
to patients who were operated during the timeframe with com-
plete data (2007–2010).
Results
Inclusion criteria were met by 17 523 patients, of which 26.7%
received an RBCT (Fig. 1). The proportion of transfused patients
decreased over the years, with 29.7% in 2007 and 24.5% in 2012
(P < 0.0001). Baseline characteristics of the included patients are
detailed in Table 1. Transfused patients were older (P < 0.0001),
presented with a lower BMI and higher ASA score (both
P < 0.0001), and had a higher burden of comorbidities, including
cardio-vascular history (P < 0.0001). Transfused patients were
more often operated on for malignancy (P < 0.0001).
The proportion of transfused patients varied according to
the type of pancreatic resection, with 20.1% (n = 1110/5504)
for distal pancreatectomy, 29.1% for pancreatoduodenectomy
(n = 3328/11 437) and 40.2% (n = 234/582) for total pancrea-
tectomy (P < 0.0001). The median operative time was longer
in transfused than non-transfused patients, with 365 (IQR:
270–473) compared with 300 (IQR: 214–393) min (P <
0.0001).
Thrity-day post-operative outcomes are detailed in Fig. 2.
Overall, 23.5% of patients experienced major morbidity, and
2.3% died within 30 days of surgery. Significantly more trans-
fused patients suffered from major morbidity and mortality.
The most common complications pertained to post-operative
infections.
Results of the multivariate analysis are presented in Table 2.
The adjusted risk estimates revealed that RBCT was indepen-
dently associated with increased 30-day major morbidity
(P < 0.0001), mortality (P < 0.0001), post-operative infections
(P < 0.0001), cardiac events (P < 0.0001), respiratory failure (P
< 0.0001) and venous thrombo-embolic events (P < 0.0001).
After adjustment, the transfused patients experienced a pro-
longed LOS (RR 1.23; 95%CI: 1.17–1.29).
The conclusions of the analyses did not change when the
cohort was restricted to calendar years with the most complete
data (2007–2010).
Discussion
This analysis of the ACS-NSQIP registry examined the associ-
ation between RBCT and 30-day outcomes after elective pan-
createctomy, with a view to providing procedure- and
practice-specific information to contribute to transfusion prac-
tices changes where needed. After adjusting for potential con-
founders, the risk of major morbidity and mortality were,
Pancreatectomies
n = 21 132
Elective pancreatectomies
n = 20 900
Final cohort
n = 17 523
<18 year sold: n = 4
Emergency surgery: n = 229
Missing data on key variables: n = 3377
Figure 1 Flow diagram of patients inclusion
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respectively, increased approximately 1.49- and 2.19-fold for
patients receiving a peri-operative RBCT. Transfused patients
also had a prolonged LOS (RR 1.27; 95% CI: 1.24–1.29).
The mechanisms underlying the relationship between RBCT
and worse post-operative outcomes have been the subject of
various hypotheses.38 Most relate to impaired immunity
through transfusion-related immunomodulation. This phe-
nomenon appears to be multifactorial and operates by reduc-
ing natural killer cells, T cells, macrophagic and monocytic
functions, and increasing the number of suppressor T cells.16
Repercussions of RBCT on the healing process after gastroin-
testinal anastomoses have previously been documented in pre-
clinical models.39,40
Previous work has highlighted increased post-operative mor-
bidity and mortality in general surgery patients receiving
RBCT.9,41 Even small RBCT amounts as low as one unit can
negatively impact outcomes, in terms of overall morbidity, sep-
sis or LOS.41 However, these analyses included more than 25
surgical procedures that all differ with regards to risk of transfu-
sion and morbidity profiles. Owing to dissection close to major
vascular structures, the highly vascularized nature of the pancre-
atic gland, and common pre-operative anaemia, pancreatic
resections present a specific risk for blood loss and the need for
a transfusion.42,43 The issue of RBCT is, therefore, particularly
relevant to a pancreas resection and has even been suggested as
a quality indicator for this procedure.44 So far, the pancreatec-
Table 1 Baseline characteristics of included patients, based on transfusion status
Characteristic Overall
(n = 17 523)
Transfused
(n = 4672)
Not transfused
(n = 12 851)
P-value
Age (years old) <40 982 (5.6) 184 (3.9) 798 (6.2) <0.0001
40–64 7826 (44.7) 1904 (40.8) 5922 (46.1)
65–74 5137 (29.3) 1432 (30.7) 3705 (28.8)
≥75 3578 (20.4) 1152 (24.7) 2426 (18.9)
Male gender 8566 (48.9) 2318 (49.6) 6248 (48.6) 0.2435
Race White 11 919 (68.0) 3010 (64.4) 8909 (69.3) <0.0001
Black 1463 (8.4) 450 (9.6) 1013 (7.9)
Other 515 (2.9) 161 (3.5) 354 (2.8)
Unknown 3626 (20.7) 1051 (22.5) 2575 (20.0)
ASA Score I 187 (1.1) 22 (0.5) 165 (1.3) <0.0001
II 5075 (29.0) 906 (19.4) 4169 (32.4)
III 11 387 (65.0) 3357 (71.9) 8030 (62.5)
IV/V 874 (5.0) 387 (8.3) 487 (3.8)
BMI <20 1139 (6.5) 357 (7.6) 782 (6.1) <0.0001
20–29 11 288 (64.4) 2984 (63.9) 8304 (64.6)
30–40 4260 (24.3) 1107 (23.7) 3153 (24.5)
≥40 727 (4.2) 180 (3.9) 547 (4.3)
Unknown 109 (0.62) 44 (0.94) 65 (0.51)
Malignant diagnosis 11 484 (65.5) 3466 (74.2) 8018 (62.4) <0.0001
Diabetes 2949 (16.8) 1069 (22.9) 1880 (14.6) <0.0001
Active smoker 3693 (21.1) 915 (19.6) 2778 (21.6) 0.0037
COPD 816 (4.7) 257 (5.5) 559 (4.4) 0.0014
Dyspnea At rest 88 (0.5) 41 (0.9) 47 (0.4) <0.0001
With moderate exertion 1398 (8.0) 438 (9.4) 960 (7.5)
Cardio-vascular comorbidity 10 721 (61.2) 3122 (66.8) 7599 (59.1) <0.0001
Bleeding disorder 506 (2.9) 207 (4.4) 299 (2.3) <0.0001
Corticosteroid use 375 (2.1) 145 (3.1) 230 (1.8) <0.0001
Weight loss > 10% 2619 (15.0) 885 (18.9) 1734 (13.5) <0.0001
Pre-operative haematocrit (%) 37.9 (34.8–41.4) 35.2 (31.5–39.0) 38.9 (36.0–42.0) <0.0001
Values are n (%) or mean [interquartile range (IQR)].
*15 481 data missing for serum albumin, 15 584 for serum bilirubin and 14 989 for INR.
ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; INR, International Normalized Ratio.
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tomy-specific evidence is limited to a few single-institution anal-
yses with limited sample sizes.20,21 Consistent with this study,
they have observed 1.5- to 2-fold higher morbidity and mortal-
ity rates with RBCT.20,21 Sets of clinical variables associated with
RBCT similar to the present study were also identified, includ-
ing BMI, smoking, weight loss, pre-operative haematocrit, surgi-
cal procedure and operative time.20,21 This outlines the
relevance of the list confounders adjusted for in this analysis.
Larger studies, some based on the ACS-NSQIP, have also been
conducted, but pooled pancreatic and liver resections.26,45 Hep-
atectomy differs significantly from pancreatectomy by its nature,
the risk for blood loss and specificities in anesthetic manage-
ment.46,47 Although the current results are similar, this study
adds to the literature by providing the first detailed and large-
scale adjusted analysis dedicated to pancreatectomy.
The restrictive use of RBCT has repeatedly been proven safe
and effective in randomized clinical trials conducted on various
populations, including surgical and acutely ill patients.48–50
Documented variations in transfusion practices expose patients
to unnecessary risks, impairs their recovery, increases health-
care costs and results in a waste of limited resources.7,20,25,51
Judicious use of RBCT is thus warranted. While RBCT are nec-
essary for some cases, most are unnecessary. Previous work indi-
cated that 46–56% of peri-operative RBCT administered in
hepato-pancreato-biliary surgery are inappropriate according to
current guidelines.21,23,26 Encouragingly, comprehensive restric-
tive transfusion initiatives comprising of patient blood manage-
ment consultants, institutional guidelines and the use of
alternative transfusion strategies have also been successful in
reducing RBCT by 15–25% in targeted surgical procedures.52–54
In particular, a significant reduction RBCT use for elective car-
diac surgery was observed across 17 United States institutions in
a before and after study including over 14 000 patients. It
was accompanied by a reduction in overall morbidity (odds
ratio – OR 0.97; 95% CI: 0.88–1.08), mortality (OR 0.53; 95%
CI: 0.37–0.74) and resource utilization.54
The main limitations of this study are inherent to its retro-
spective nature and the use of a large database, especially
information and selection bias. The ACS-NSQIP data have the
advantage of being abstracted by trained healthcare professional
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
Major morbidity Mortality Post-operative
infections
Cardiac events Respiratory failure Venous thrombo-
embolic events
Transfused   1540 (33.0) 214 (4.6) 1427 (30.5) 153 (3.3) 619 (13.3) 234 (5.0)
335 (2.6)493 (3.8)162 (1.3)2655 (20.7)195 (1.5)Not transfused 2573 (20.0)
P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Values are n (%)
Figure 2 Short-term post-pancreatectomy outcomes, based on transfusion status
Table 2 Association between RBCT and short-term post-pancreatectomy outcomes, in the entire cohort
Outcomes Unadjusted Adjusteda
Relative risk (95% CI) P-value Relative risk (95% CI) P-value
Major morbidity 1.65 (1.56–1.74) <0.0001 1.49 (1.39–1.60) <0.0001
Mortality 3.12 (2.56–3.79) <0.0001 2.19 (1.76–2.73) <0.0001
Post-operative infection 1.48 (1.40–1.56) <0.0001 1.37 (1.29–1.45) <0.0001
Cardiac events 2.65 (2.12–3.32) <0.0001 2.26 (1.77–2.90) <0.0001
Respiratory failure 3.83 (3.38–4.33) <0.0001 2.83 (2.47–3.25) <0.0001
Venous thrombo-embolic events 1.97 (1.66–2.34) <0.0001 1.65 (1.36–2.00) <0.0001
*Adjusted for: age, gender, race, BMI, ASA class, HCT, bilirubin, INR, cardiac comorbidities, bleeding disorder, procedure, malignant post-opera-
tive diagnosis, and operative time.
RBCT, Red Blood Cell Transfusion; CI, Confidence Interval.
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abstractors and being validated by audits. Its accuracy and relia-
bility have been repeatedly shown.31–34 As previously described,
patterns and impact of missing data were explored and taken
into consideration in the analysis. Differences in baseline char-
acteristics of transfused patients were indicative of how a higher
degree of frailty predisposed them to receive RBCT. The analysis
was adjusted for known and relevant variables associated with
RBCT in robust regression models. Other limitations include
the lack of some variables in ACS-NSQIP. First, cancer staging
or disease severity information, including the need for venous
resection, was lacking. These factors can render the resection
technically more challenging and increase the risk for both a
transfusion and post-operative morbidity. The type of surgical
procedure and operative time were used as surrogate markers
for technical complexity and corrected for. Second, clinical vari-
ables dictating the indication for RBCT were not available (e.g.
pre-transfusion hemoglobin, haemodynamic parameters and
symptoms). Many factors play a role in the decision to transfuse
a patient, and some may contribute to increased morbidity
independently of RBCT. Therefore, this analysis could not tease
out the exact portion of incremental morbidity attributable to
unnecessary RBCT. Similarly, determining whether RBCT was
directly causative of morbidity or a response to complication
remains challenging. Only RBCT administered during the first
72 h following surgery were considered. Thus, transfusion is
likely to have happened prior to the complication.
When gaps between practice and guidelines exist, successful
and lasting uptake of guidelines requires tailored approaches
driven by practice-specific data.29,55 Owing to the unique and
comprehensive data from the ACS-NSQIP, this study repre-
sents the largest multi-institutional and only specific appraisal
of the impact of RBCT on post-pancreatectomy short-term
outcomes, and provides results with high external validity. It
provides procedure-specific evidence to raise awareness about
the need to minimize the use of RBCT when they can be
safely avoided for elective pancreatectomy. Stronger proce-
dure-specific evidence to support a change in practice could
be obtained with a randomized study design aimed at com-
paring the impact of a comprehensive blood management
strategy focused on restrictive transfusion guidelines
compared with traditional practice on post-pancreatectomy
outcomes.
Conclusion
Peri-operative RBCT was independently associated with
increased 30-day major morbidity and mortality, and a pro-
longed LOS in patients undergoing pancreatectomy, after
adjusting for potential confounders. These data further the
rationale to attempt to reduce the use of RBCT after elective
pancreatectomy when they can be safely avoided. Future stud-
ies should focus on the impact of interventions to minimize
the use of RBCT after elective pancreatectomy.
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